https://www.selleckchem.com/products/aunp-12.html Immunosuppression is an important factor in the incidence of infections in transplant recipient. Few studies are available on the management of immunosuppression (IS) treatment in the liver transplant (LT) recipients complicated with infection. The aim of this study is to describe our experience in the management of IS treatment during bacterial bloodstream infection (BSI) in LT recipients and assess the effect of temporary IS withdrawal on 30 d mortality of recipients presenting with severe infection. To assess the effect of temporary IS withdrawal on 30 d mortality of LT recipients presenting with severe infection. A retrospective study was conducted with patients diagnosed with BSI after LT in the Department of Liver Surgery, Renji Hospital from January 1, 2016 through December 31, 2017. All recipients diagnosed with BSI after LT were included. Univariate and multivariate Cox regression analysis of risk factors for 30 d mortality was conducted in the LT recipients with Gram-negative bacterial (GNB) id complete IS withdrawal (adjusted hazard ratio 12.65, = 0.019) were independent risk factors for 30 d mortality in patients with GNB infections after LT. IS reduction is more frequently associated with GNB infection than GPB infection in LT recipients. Complete IS withdrawal should be cautious due to increased risk of mortality in LT recipients complicated with BSI. Gut tryptophan (Trp) metabolites are produced by microbiota and/or host metabolism. Some of them have been proven to promote or inhibit colorectal cancer (CRC) and animal models. We hypothesized that there is an alteration of gut Trp metabolism mediated by microbiota and that it might be involvedin the pathogenesis of cancer in patients with CRC. To investigate the features of Trp metabolism in CRC and the correlation between fecal Trp metabolites and gut microbiota. Seventy-nine patients with colorectal neoplastic lesions (33 with colon adenoma and 46 wit